GB201915829D0 - Compounds, compositions and therapeutic uses thereof - Google Patents
Compounds, compositions and therapeutic uses thereofInfo
- Publication number
- GB201915829D0 GB201915829D0 GBGB1915829.4A GB201915829A GB201915829D0 GB 201915829 D0 GB201915829 D0 GB 201915829D0 GB 201915829 A GB201915829 A GB 201915829A GB 201915829 D0 GB201915829 D0 GB 201915829D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compositions
- compounds
- therapeutic uses
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1915829.4A GB201915829D0 (en) | 2019-10-31 | 2019-10-31 | Compounds, compositions and therapeutic uses thereof |
| PCT/GB2020/052745 WO2021084265A1 (en) | 2019-10-31 | 2020-10-30 | Isoquinoline derivatives as sik2 inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1915829.4A GB201915829D0 (en) | 2019-10-31 | 2019-10-31 | Compounds, compositions and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201915829D0 true GB201915829D0 (en) | 2019-12-18 |
Family
ID=69059109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1915829.4A Ceased GB201915829D0 (en) | 2019-10-31 | 2019-10-31 | Compounds, compositions and therapeutic uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201915829D0 (en) |
| WO (1) | WO2021084265A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (en) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Quinazoline derivative process for the preparation of the same pharmaceutical composition and process for the production of an antiangiogenic effect and / or reduction of vascular permeability in a warm-blooded animal |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| TR200500745T2 (en) | 1999-02-10 | 2005-05-23 | Astrazeneca Ab | Quinazoline derivatives as inhibitors of vascular development. |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| KR20030022264A (en) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | Colchinol derivatives as angiogenesis inhibitors |
| WO2008122614A1 (en) * | 2007-04-06 | 2008-10-16 | Novartis Ag | 2, 6-naphthyridine derivatives as protein kinase modulators |
| EA026115B1 (en) * | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| CA2863132A1 (en) * | 2012-01-30 | 2013-08-08 | F. Hoffmann-La Roche Ag | Isoquinoline and naphthyridine derivatives |
| AU2017291812B2 (en) | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| JOP20190257A1 (en) * | 2017-04-28 | 2019-10-28 | Novartis Ag | 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors |
-
2019
- 2019-10-31 GB GBGB1915829.4A patent/GB201915829D0/en not_active Ceased
-
2020
- 2020-10-30 WO PCT/GB2020/052745 patent/WO2021084265A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021084265A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2592822B (en) | Therapeutic compositions | |
| IL285302A (en) | Compounds, compositions and methods | |
| IL286079B1 (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
| GB202017595D0 (en) | Compositions, and methods and uses relating thereto | |
| GB201901099D0 (en) | Methods, uses and compositions | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| GB202102895D0 (en) | Novel compounds, compositions and therapeutic uses thereof | |
| IL284765A (en) | 1,8-naphthyridinone compounds and uses thereof | |
| PL3908321T3 (en) | Pharmaceutical composition | |
| IL287120A (en) | Compounds, compositions and methods | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| EP3873446A4 (en) | Therapeutic compounds and compositions | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| GB201915829D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| IL285728A (en) | Pharmaceutical composition | |
| IL276125A (en) | Dihydroindolizinone derivative compounds, compositions comprising same and uses thereof | |
| PL3949952T3 (en) | Pharmaceutical composition | |
| GB2579240B (en) | New processes, compositions and medical uses | |
| IL287316A (en) | Compounds and compositions | |
| HK40060891B (en) | Therapeutic compositions | |
| GB201909868D0 (en) | Therapeutic compositions | |
| HK40042383B (en) | Therapeutic compositions | |
| HK40042383A (en) | Therapeutic compositions | |
| HK40060600A (en) | Therapeutic compounds and compositions | |
| HK40060598A (en) | Therapeutic compounds and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |